In 2010, this was niche research. In 2026, it’s standard care. The science of slowing myopia progression in children has matured dramatically — and for families who don’t want their kid in contact lenses or dealing with atropine drops side effects, myopia control spectacle lenses now offer a legitimate third path.
The numbers behind the urgency: the NIH’s National Eye Institute projects that nearly half of the global population will have myopia by 2050, up from roughly 23% in 2000. High myopia (above -6.00D) carries substantial risks of retinal detachment, glaucoma, and macular degeneration. Slowing the rate of progression — even by 30–50% — meaningfully reduces lifetime risk. That’s what these lenses are designed to do.
The Three Main Platforms
Hoya MiYOSMART (DIMS Technology)
The MiYOSMART lens uses Defocus Incorporated Multiple Segments (DIMS) technology — a central clear zone surrounded by a honeycomb of 1.03D defocus lenslets that reduce the hyperopic peripheral defocus signal believed to drive axial elongation.
Evidence: The landmark 2-year randomized controlled trial published in the British Journal of Ophthalmology (2019) showed DIMS lenses slowed myopia progression by 60% and axial elongation by 62% compared to single vision lenses. A 6-year follow-up data set (2022) confirmed durability of the effect.
US availability: MiYOSMART lenses are sold through authorized Hoya partner practices. Cost: $400–$700 per pair (lens cost only; frames extra).
Essilor Stellest (H.A.L. Technology)
Essilor’s Stellest uses Highly Aspherical Lenslets (HAL) — a constellation of 1.00D convergent lenslets arranged in 11 concentric rings around the clear central optical zone. Different geometry from DIMS; similar mechanism.
Evidence: The 3-year randomized trial published in Ophthalmic and Physiological Optics (2021) showed 67% reduction in myopia progression vs. single vision lenses. One of the strongest published datasets in the field.
US availability: Essilor/Luxottica network. Cost: $450–$750 per pair.
SightGlass Vision DOT Lenses (Diffusion Optics Technology)
SightGlass uses a different approach — light scattering via micro-dots in the lens that reduce contrast signaling to the peripheral retina, rather than defocus lenslets. FDA Breakthrough Device Designation was granted in 2020.
Evidence: The 3-year pivotal CYPRESS trial results reported 67% reduction in myopia progression in the higher-contrast-reduction arm. Cost: $500–$900 per pair.
| Lens Platform | Technology | Clinical Evidence | Annual Cost (lens only) |
|---|---|---|---|
| Hoya MiYOSMART | DIMS lenslets | 60–62% reduction, 6-yr data | $400–$700 |
| Essilor Stellest | HAL lenslets | 67% reduction, 3-yr RCT | $450–$750 |
| SightGlass Vision DOT | Diffusion optics | 67% reduction, 3-yr CYPRESS | $500–$900 |
| Standard single vision (comparison) | — | No myopia control effect | $80–$300 |
What the Total Annual Cost Looks Like
Myopia control spectacle lenses are a recurring annual cost. Kids’ prescriptions change — often every 6–12 months in the peak progression years (ages 8–14) — so you’re not buying one pair and done.
Budget realistically:
- Lens cost: $400–$900/pair
- Frame cost: $50–$300 (kids’ durable frames)
- Eye exam: $80–$150/year
- Annual total: $530–$1,350/year
- Total across 6-year peak progression period: $3,200–$8,100
That sounds like a lot. Compare it to the alternative: single vision lenses ($80–$300/pair × 6 years = $480–$1,800) but with unchecked progression potentially adding 1.00–2.00D extra myopia by the end of that period. At -6.00D instead of -4.00D, your child faces a substantially elevated lifetime risk of macular degeneration and retinal complications.
Vision insurance plans (VSP, EyeMed, Spectera) treat myopia control lenses like specialty lenses — they apply the standard lens benefit (typically $150–$250 allowance) and you pay the difference. There’s no special myopia control benefit at most plans. The contact lens exam and annual exam are covered normally. HSA and FSA accounts can be used for the prescription lens purchase, so set aside FSA funds if available — it reduces the effective cost by your marginal tax rate (typically 22–32% for the relevant income range).
Comparing Myopia Control Options: Glasses vs. Alternatives
Myopia control spectacle lenses aren’t the only option — they sit in a menu of approaches:
| Approach | Efficacy | Annual Cost | Age/Contact Tolerance |
|---|---|---|---|
| HAL/DIMS/DOT spectacles | 60–67% slowdown | $500–$900 | Any age, no contact tolerance needed |
| Orthokeratology (Ortho-K) | 40–60% slowdown | $1,200–$2,000 | Ages 8+, must tolerate rigid lenses overnight |
| MiSight 1-day contacts | ~52% slowdown | $700–$1,200 | Ages 8+, must tolerate daily soft contacts |
| Atropine 0.05% drops | 50–67% slowdown | $50–$300 | Any age, side effects (light sensitivity, near blur) |
For children too young for contacts or with contact intolerance, myopia control glasses are often the first-line choice. For children already in contacts, MiSight or ortho-K may be preferred.
Not all optometrists carry or are trained in myopia control spectacle lenses. This is a newer area of practice — seek out practices that specifically list “myopia management” on their website or that have the International Myopia Institute (IMI) guidelines integrated into their protocols. A general practice that doesn’t routinely prescribe these lenses may suggest single-vision glasses by default. If your child is progressing by more than -0.50D per year, ask specifically whether myopia control lenses are an option.
Starting Age and When to Expect Results
The evidence supports starting myopia control as soon as progression is confirmed — ideally before age 10 and with at least 2 measurements 6–12 months apart showing progression. Children who start earlier typically achieve better absolute outcomes because more of the progression period remains.
Myopia control glasses slow the rate of change — they don’t stop it completely. A realistic expectation: instead of -1.00D per year, your child may progress at -0.35–0.40D per year. Over 5 years, that’s the difference between -5.00D and -2.00D of additional myopia — a meaningful clinical outcome.
Track axial length (the physical length of the eye) if your optometrist has an IOL Master or similar device. Changes in axial length are a more sensitive marker of progression than refraction alone, and monitoring it gives the most accurate picture of whether treatment is working.